Complications with the use of botulinum toxin

Dermatologic Clinics

Volumn 22, Issue 2, 2004, Pages 197-205

  Klein, Arnold W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; APRACLONIDINE; BOTULINUM TOXIN A; PHENYLEPHRINE;

ANTIBODY PRODUCTION; BLEPHAROSPASM; CLINICAL TRIAL; DIPLOPIA; DRUG EFFECT; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; DYSTONIA; EATON LAMBERT SYNDROME; ECCHYMOSIS; ECTROPION; EDEMA; ELECTROMYOGRAPHY; ERYTHEMA; EYE DISEASE; EYE INJURY; FATIGUE; FLU LIKE SYNDROME; HEADACHE; HEALTH HAZARD; HEMIFACIAL SPASM; HUMAN; HYPERHIDROSIS; HYPESTHESIA; IMMUNOGENICITY; INJECTION PAIN; MALAISE; MEIGE DISEASE; MUSCLE SPASM; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NAUSEA; PERFORATION; PREGNANCY; PRIORITY JOURNAL; PTOSIS; RETROBULBAR HEMORRHAGE; REVIEW; SPASTICITY; STRABISMUS; TENSION HEADACHE;

BOTULINUM TOXIN TYPE A; HUMANS; INFORMED CONSENT; INJECTIONS, INTRAMUSCULAR; NEUROMUSCULAR AGENTS; SKIN AGING; SPASM;

EID: 2442505501     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(03)00122-0     Document Type: Review

References (46)

1. Carruthers A, Carruthers J. History of the cosmetic use of botulinum A exotoxin. Dermatol Surg 1998;24:1168-70.
2. Carruthers A, Carruthers J. Clinical indications and injection technique for the cosmetic use of botulinum A exotoxin. Dermatol Surg 1998;24:1189-94.
3. Klein AW, Mantell A. Electromyographic guidance in injecting botulinum toxin. Dermatol Surg 1998;24:1184-6.
4. Binder WJ, Blitzer A, Brin MF. Treatment of hyperfunctional lines of the face with botulinum toxin A. Dermatol Surg 1998;24:1198-205.
5. Klein AW, Glogau RG. Botulinum toxin: beyond cosmesis. Arch Dermatol 2000;136:539-41.
6. Lamanns C. The most poisonous poison. Science 1969;130:763-72.
7. Dertzbaugh MT, West MW. Mapping of protective and cross-reactive domains of the type A neurotoxin of Clostridium botulinum. Vaccine 1996;16:1538-44.
8. Keen M, Blitzer A, Aviv J, et al. Botulinum toxin A therapy for hyperkinetic facial lines: results of a double-blind, placebo-controlled study. Plast Reconstr Surg 1994;94:94-9.
9. Somers E, DasGupta BR. Clostridium botulinum type A, B, C1 and E produce proteins with or without hemagglutinating activity: Do they share common amino acid sequences and genes? J Protein Chem 1991;10:415-25.
10. Sakaguchi G. Clostridium botulinum toxins. Pharmacol Ther 1983;19:165-94.
11. Bonventre PF, Kempe LL. Physiology of toxin production by Clostridium botulinum types A and B. III. Effect of pH and temperature during incubation on growth, autolysis, and toxin production. Appl Microbiol 1959;7:374-7.
12. Townsend CT, Yee L, Mercer WA. Inhibition of the growth of Clostridium botulinum by acidification. Food Res 1954;19:1-7.
13. Baffi RA, Garnick RL. Quality control issues in the analysis of lyophilized proteins. Dev Biol (Basel) 1991;74:181-4.
14. Borodic GE, Ferranter R. Orbicularis muscle histology after repetitive injections of botulinum A toxin. Presented at the annual meeting of American Academy of Ophthalmology. Atlanta, Georgia, October 28-November 1, 1990.
15. Sloop RR, Cole BA, Escutin RO. Human response to botulinum toxin injection: type B compared with type A. Neurology 1999;49:189-94.
16. Jankovic J, Brin MF. Botulinum toxin: historical perspective and potential new indications. Muscle Nerve 1997;20(Supp 6):S129-45.
17. Brin MF. Botulinum toxin: new and expanded indications. Eur J Neurol 1997;4:59-66.
18. Mahant N, Clouston PD, Lorentz IT. The current use of botulinum toxin. J Clin Neurosci 2000;7:389-94.
19. Lange DI, Brin MF, Warner CL, et al. Distant effects of local injection of botulinum toxin. Muscle Nerve 1987;10:552-5.
20. Olney RK, Aminoff MJ, Gelb DJ, et al. Neuromuscular effects distant from the site of botulinum neurotoxin injection. Neurology 1988;38:1780-3.
21. Report of the Therapeutics in Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: the clinical usefulness of botulinum toxin A in treating neurologic disorders. Neurology 1990;40:1332-6.
22. Bhatia KP, Münchau A, Thompson PD, et al. Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases. J Neurol Neurosurg Psychiatry 1999;67:90-3.
23. Lingua RW. Sequelae of botulinum toxin injection. Am J Ophthalmol 1985;100:305-7.
24. Burns CL, Gammon JA, Gemmill MC. Ptosis associated with botulinum toxin treatment of strabismus and blepharospasm. Ophthalmology 1986;93:1621-7.
25. Scott AB. Botulinum toxin treatment of strabismus (Focal Points 1989 Clinical Modules for Ophthalmologists, No. 7). San Francisco: American Academy of Ophthalmology; 1989.
26. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995;45:1743-6.
27. Gonnering RS. Negative antibody response to longterm treatment of facial spasm with botulinum toxin. Am J Ophthalmol 1988;105:313-5.
28. Mezaki T, Kaji R, Kohara N, et al. Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: a double-blind, controlled study. Neurology 1995;45:506-8.
29. Ludlow CL, Hallett M, Rhew K, et al. Therapeutic use of type F botulinum toxin [letter]. N Engl J Med 1992;326:349-50.
30. Sankhla C, Jankovic J, Duane D. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord 1998;13:150-4.
31. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type Aresistant cervical dystonia. Neurology 1999;53:1431.
32. Göschel H,Wohlfaqrth K, Frevert J, et al. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies -therapeutic consequences. Exp Neurol 1997;147:96-102.
33. NIH. Clinical use of botulinum toxin. National Institutes of Health Consensus Development Conference. NIH Consens Statement, November 12 - 14, 1990;8:1-20.
34. Borodic G, Johnson E, Goodnough M, et al. Botulinum toxin therapy, immunologic resistance and problems with available materials. Neurology 1996;46:26-9.
35. Klein A. Cosmetic therapy with botulinum toxin: anecdotal memoirs. Dermatol Surg 1996;22:757-9.
36. Blitzer A, Brin MF, et al. Botulinum toxin for the treatment of hyperfunctional lines of the face. Arch Otolaryngol Head Neck Surg 1993;119:1018-22.
37. Carruthers JDA, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 1992;18:17-21.
38. Hambleton P, Moore AP. Botulinum neurotoxins: origin, structure, molecular actions, and antibody. In: Moore P, editor. Handbook of botulinum toxin treatment. Oxford: Blackwell Science; 1995. p. 16-27.
39. Alam M, Arndt KA, Dover JS. Severe, intractable headache following injection with botulinum A exotoxin. J Am Acad Dermatol 2002;46(1):62-5.
40. Burns RL. Complications of botulinum exotoxin. Presented at the 25th Annual Clinical and Scientific Meeting of the ASDS. Portland, OR, May 13-17, 1998.
41. Foster JA, Barnhorst D, Papay F, et al. The use of botulinum A toxin to ameliorate facial kinetic frown lines. Ophthalmology 1996;103:618-22.
42. Fraenkel AS, Kamer FM. Chemical brow lift. Arch Otolaryngol Head Neck Surg 1998;124:321-3.
43. Brandt FS, Bellman B. Cosmetic use of botulinum A exotoxin for the aging neck. Dermatol Surg 1998;24:1232-4.
44. Bushara KO, Jones JW, Park DM, et al. Botulinum toxin and sweating [abstract]. Mov Disord 1995;10:391.
45. Silberstein S, Mathew N, Saper J, et al. Botulinum toxin type A as a migraine preventive treatment. Headache 2000;40:445-50.
46. Brin M.F., Swope D.M., Abassi S., et al. Botulinum toxin type A (Botox) for migraine: double blind, placebo controlled, region specific evaluation [poster 1196]. Poster presented at the Headache World 2000. London, September 3-7, 2000